Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
Abstract Background Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy. Methods We evaluated clinical status in patients with the SARS-CoV-2 delta...
Main Authors: | Xuejiao Liao, Dapeng Li, Jie Liu, Zhi Liu, Zhenghua Ma, Jingke Dong, Xiangyi Yang, Dan Shu, Jing Yuan, Lei Liu, Zheng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Virology Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12985-022-01944-6 |
Similar Items
-
Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
by: Bing Zhou, et al.
Published: (2022-05-01) -
Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
by: Chloé Dimeglio, et al.
Published: (2022-08-01) -
Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study
by: Yi Guo, et al.
Published: (2022-07-01) -
Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
by: Liguo Zhu, et al.
Published: (2023-12-01) -
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
by: Shohei Yamamoto, et al.
Published: (2023-05-01)